Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 122

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 122
---
 combination with targeted small molecule therapy in a variety of tumor types. IND-enabling work is ongoing and first global clinical trials, including in China, are expected to initiate in late 2025. Beyond these clinical stage candidates and ATTC candidates, we continue to research and discover new types of drug candidates, including those that address cancer-related apoptosis, cell signaling, epigenetics and protein translation and other novel technologies. The following picture contrasts the difference between the traditional ADC and the pioneering ATTC.

Table of Contents

Manufacturing

We have a drug product manufacturing facility in Suzhou which manufactures both clinical and commercial supplies for fruquintinib and surufatinib. Our new drug product facility in Shanghai is expected to increase our novel drug product manufacturing capacity by over five times. All our clinical supplies have completed technology transfer and are now being produced by our Shanghai factory. Our commercial supplies have also gradually migrated to this new facility, with significant production cost savings.

A commercial batch of savolitinib, which previously relied on a third-party manufacturer, was manufactured in the Shanghai factory in late 2024. This marked the first approval and delivery of commercial production from the Shanghai factory. We plan to complete site application and submission for surufatinib and fruquintinib in the second half of 2025, paving the way for their commercial production at the Shanghai factory.

We have established the FRUZAQLA® supply chain for the global markets including U. S., E. U. and Japan. Two drug product sites for supplying fruquintinib to the U. S. market have been qualified: our own facility in Suzhou and a second site in Switzerland. Both sites have already successfully delivered commercial batches for product launches in several E. U. countries, the United Kingdom and Switzerland during 2024.

The ATTC facility has commenced production of GMP-grade materials tailored for IND applications and clinical supply. For future ATTC production, we may consider further expansion of our facilities and/or external collaboration to scale up our biologics capacity.

Table of Contents

Other Ventures

Our Other Ventures include drug marketing and distribution platforms covering about 290 cities and towns in China, primarily focusing on prescription drugs through joint ventures. In December 2024, we entered into agreements to dispose of a 45% equity interest in Shanghai Hutchison Pharmaceuticals to focus on our global innovative drug discovery and development businesses.

In 2024, our Other Ventures’ consolidated revenue decreased 14% to $266.8 million